You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SBIR Phase I:Creation of antimicrobial MyoMatrix for functional muscle regeneration in a porcine model of volumetric muscle loss

    SBC: GENASSIST INC            Topic: BM

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop an antimicrobial muscle-regenerating biomaterial into a commercial-ready product and address volumetric muscle loss injuries. In the context of defense medicine, severe muscle trauma often occurs in environments where external factors such as sterility are not well-controlled. Th ...

    SBIR Phase I 2023 National Science Foundation
  2. SBIR Phase I:Directed evolution of site-specific bacterial transposase genes to alter specificity and efficiency of insertion of large DNA segments into restorable gene fusions

    SBC: SYNTHETIC VECTOR DESIGNS, LLC            Topic: BT

    The broader impact of this Small Business Innovation Research (SBIR) Phase I project will be to develop methods to facilitate the efficient, reproducible insertion of large DNA segments into stable locations on bacterial vectors, viral and non-viral shuttle vectors, and the chromosomes of prokaryotic and eukaryotic host cells comprising novel target sequences plus helper and donor vectors that cou ...

    SBIR Phase I 2023 National Science Foundation
  3. SBIR Phase I: Reactive Cyclic Induction Marine Diesel Emissions Reduction Monitoring and Delivery System Project

    SBC: STec. Technology, Inc.            Topic: ET

    The broader impact of this Small Business Innovation Research (SBIR) Phase I project is the potential reduction of toxic nitrogen oxides (NOx) and harmful carbon dioxide (CO2) emissions from marine diesel engines. There are approximately 4 million diesel-powered craft in use globally, emitting approximately one billion tons of CO2 and 100 million tons of NOx annually. This project seeks to remove ...

    SBIR Phase I 2023 National Science Foundation
  4. Next Generation Microlayer Annular Co-Extrusion

    SBC: Guill Tool & Engineering Co, Inc.            Topic: C5620c

    Annular extruded plastics are in everything from fuel lines, hoses, pipes, and wires to catheters, medical tubing, and stents and makes up about ? of the $200B extruded plastics market. Extrusion manufacturing is a major processor of the $600B raw plastics industry, which produces 380 million metric tons of material each year. The production of these materials accounts for 4% of oil consumption an ...

    SBIR Phase I 2023 Department of Energy
  5. Computer Vision Under Strict Security Constraints: Applications for Robotics

    SBC: MONA MARIE CORPORATION            Topic: X224OCSO1

    Proposed is robotic lawn mower developed and commercialized by the proposing company – Hire Henry. The focus of this Phase I proposal is to quantify the potential impact for fully autonomous, fully electric robotic lawn mowing on United States Air Force Bases. This proposal lays the ground work for future work, which focuses on developing computer vision models for robotic mowing specifically f ...

    SBIR Phase I 2023 Department of DefenseAir Force
  6. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. 3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring

    SBC: Axioforce LLC            Topic: NIBIB

    PROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.

    SBC: Shift Pharmaceuticals Holdings, Inc.            Topic: 106

    Abstract: The objective of this project is to perform the required (and previously approved) IND-enabling experimental work for E1v1.11, a novel drug candidate for Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is the leading genetic cause of infantile death worldwide, occurring in ~1:10,000 live births. The gene responsible for SMA is called survival motor neuron-1 (SM ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.

    SBC: Antiger Therapeutics Inc.            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT The mission of Antiger Therapeutics Inc. is to develop novel immunotherapies for transplant recipients to improve long-term graft outcomes and minimize adverse effects. Antibody-mediated rejection (AMR) is a leading cause of graft loss, with over 3000 new cases per year in the United States and estimated market size of $90 million. However, this estimate is likely to under ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    SBC: EPIVAX, INC.            Topic: NIAID

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government